Genentech mPI3Kα Degrader
isoform-selective mutant PI3Kα degrader oral <9 mg QD, Ph. III in HR+/HER2- BC from cellular characterization of PI3Ki and opt. inovalisib (GDC-0077) Genentech, South San Francisco, CA
Molecules of the Month - 2021 Molecules of the Year Nominees
- Pfizer CoV-2 MPro Inhibitor
- Arvinas ER Chimeric Degrader
- Kronos CDK9 Inhibitor
- Merck PCSK9 Inhibitors
- Mirati KRASG12D Inhibitor
- Takeda EGFRex20 Inhibitor
- Lilly GLP Molecular Glue
- RevMed KRASG12C Tricomplex Inhibitor
- Genentech mPI3Kα Degrader
- H3Bio SF3b Splicing Modulator
- BioCryst Kallikrein Inhibitor
- Genentech ER Degrader
- Pfizer CoV-2 MPro Inhibitor
- Arvinas ER Chimeric Degrader
- Kronos CDK9 Inhibitor
- Merck PCSK9 Inhibitors
- Mirati KRASG12D Inhibitor
- Takeda EGFRex20 Inhibitor
- Lilly GLP Molecular Glue
- RevMed KRASG12C Tricomplex Inhibitor
- Genentech mPI3Kα Degrader
- H3Bio SF3b Splicing Modulator
- BioCryst Kallikrein Inhibitor
- Genentech ER Degrader